vs

Side-by-side financial comparison of COGENT COMMUNICATIONS HOLDINGS, INC. (CCOI) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

COGENT COMMUNICATIONS HOLDINGS, INC. is the larger business by last-quarter revenue ($240.5M vs $151.7M, roughly 1.6× Tarsus Pharmaceuticals, Inc.). Tarsus Pharmaceuticals, Inc. runs the higher net margin — -5.5% vs -12.8%, a 7.3% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -4.7%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-43.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -4.9%).

Cogent Communications Holdings, Inc. is a multinational internet service provider based in the United States. Cogent's primary services consist of Internet access and data transport, offered on a fiber optic, IP data-only network, along with colocation in data centers.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

CCOI vs TARS — Head-to-Head

Bigger by revenue
CCOI
CCOI
1.6× larger
CCOI
$240.5M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+133.1% gap
TARS
128.4%
-4.7%
CCOI
Higher net margin
TARS
TARS
7.3% more per $
TARS
-5.5%
-12.8%
CCOI
More free cash flow
TARS
TARS
$56.0M more FCF
TARS
$13.0M
$-43.0M
CCOI
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-4.9%
CCOI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCOI
CCOI
TARS
TARS
Revenue
$240.5M
$151.7M
Net Profit
$-30.8M
$-8.4M
Gross Margin
46.6%
Operating Margin
-4.7%
-5.3%
Net Margin
-12.8%
-5.5%
Revenue YoY
-4.7%
128.4%
Net Profit YoY
28.9%
63.8%
EPS (diluted)
$-0.63
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCOI
CCOI
TARS
TARS
Q4 25
$240.5M
$151.7M
Q3 25
$241.9M
$118.7M
Q2 25
$246.2M
$102.7M
Q1 25
$247.0M
$78.3M
Q4 24
$252.3M
$66.4M
Q3 24
$257.2M
$48.1M
Q2 24
$260.4M
$40.8M
Q1 24
$266.2M
$27.6M
Net Profit
CCOI
CCOI
TARS
TARS
Q4 25
$-30.8M
$-8.4M
Q3 25
$-41.5M
$-12.6M
Q2 25
$-57.8M
$-20.3M
Q1 25
$-52.0M
$-25.1M
Q4 24
$-43.3M
$-23.1M
Q3 24
$-63.1M
$-23.4M
Q2 24
$-32.3M
$-33.3M
Q1 24
$-65.3M
$-35.7M
Gross Margin
CCOI
CCOI
TARS
TARS
Q4 25
46.6%
Q3 25
45.6%
Q2 25
44.2%
Q1 25
44.4%
Q4 24
38.5%
Q3 24
37.2%
Q2 24
40.0%
Q1 24
36.5%
Operating Margin
CCOI
CCOI
TARS
TARS
Q4 25
-4.7%
-5.3%
Q3 25
-7.5%
-12.2%
Q2 25
-12.8%
-21.6%
Q1 25
-16.3%
-33.5%
Q4 24
-13.2%
-36.8%
Q3 24
-22.5%
-52.3%
Q2 24
-18.1%
-81.6%
Q1 24
-22.3%
-136.5%
Net Margin
CCOI
CCOI
TARS
TARS
Q4 25
-12.8%
-5.5%
Q3 25
-17.2%
-10.6%
Q2 25
-23.5%
-19.8%
Q1 25
-21.1%
-32.1%
Q4 24
-17.2%
-34.8%
Q3 24
-24.5%
-48.7%
Q2 24
-12.4%
-81.6%
Q1 24
-24.5%
-129.4%
EPS (diluted)
CCOI
CCOI
TARS
TARS
Q4 25
$-0.63
$-0.17
Q3 25
$-0.87
$-0.30
Q2 25
$-1.21
$-0.48
Q1 25
$-1.09
$-0.64
Q4 24
$-0.89
$-0.57
Q3 24
$-1.33
$-0.61
Q2 24
$-0.68
$-0.88
Q1 24
$-1.38
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCOI
CCOI
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$148.5M
$417.3M
Total DebtLower is stronger
$1.7B
$72.4M
Stockholders' EquityBook value
$-63.8M
$343.4M
Total Assets
$3.1B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCOI
CCOI
TARS
TARS
Q4 25
$148.5M
$417.3M
Q3 25
$147.1M
$401.8M
Q2 25
$213.7M
$381.1M
Q1 25
$153.8M
$407.9M
Q4 24
$198.5M
$291.4M
Q3 24
$279.2M
$317.0M
Q2 24
$384.4M
$323.6M
Q1 24
$118.4M
$298.5M
Total Debt
CCOI
CCOI
TARS
TARS
Q4 25
$1.7B
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$1.5B
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
CCOI
CCOI
TARS
TARS
Q4 25
$-63.8M
$343.4M
Q3 25
$-39.2M
$335.1M
Q2 25
$46.7M
$332.6M
Q1 25
$142.8M
$342.5M
Q4 24
$222.8M
$224.5M
Q3 24
$323.6M
$237.5M
Q2 24
$415.5M
$252.2M
Q1 24
$500.6M
$275.2M
Total Assets
CCOI
CCOI
TARS
TARS
Q4 25
$3.1B
$562.2M
Q3 25
$3.1B
$534.6M
Q2 25
$3.3B
$495.0M
Q1 25
$3.1B
$500.8M
Q4 24
$3.2B
$377.0M
Q3 24
$3.2B
$376.3M
Q2 24
$3.3B
$376.8M
Q1 24
$3.1B
$349.3M
Debt / Equity
CCOI
CCOI
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
6.53×
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCOI
CCOI
TARS
TARS
Operating Cash FlowLast quarter
$-6.0M
$19.3M
Free Cash FlowOCF − Capex
$-43.0M
$13.0M
FCF MarginFCF / Revenue
-17.9%
8.6%
Capex IntensityCapex / Revenue
15.4%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-198.1M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCOI
CCOI
TARS
TARS
Q4 25
$-6.0M
$19.3M
Q3 25
$3.1M
$18.3M
Q2 25
$-44.0M
$-29.4M
Q1 25
$36.4M
$-20.7M
Q4 24
$14.5M
$-22.2M
Q3 24
$-20.2M
$-8.7M
Q2 24
$-22.2M
$-14.4M
Q1 24
$19.2M
$-37.8M
Free Cash Flow
CCOI
CCOI
TARS
TARS
Q4 25
$-43.0M
$13.0M
Q3 25
$-33.1M
$16.3M
Q2 25
$-100.2M
$-30.4M
Q1 25
$-21.7M
$-21.2M
Q4 24
$-31.6M
$-22.3M
Q3 24
$-79.5M
$-8.9M
Q2 24
$-70.9M
$-15.4M
Q1 24
$-21.7M
$-38.0M
FCF Margin
CCOI
CCOI
TARS
TARS
Q4 25
-17.9%
8.6%
Q3 25
-13.7%
13.8%
Q2 25
-40.7%
-29.6%
Q1 25
-8.8%
-27.1%
Q4 24
-12.5%
-33.5%
Q3 24
-30.9%
-18.6%
Q2 24
-27.2%
-37.8%
Q1 24
-8.1%
-137.5%
Capex Intensity
CCOI
CCOI
TARS
TARS
Q4 25
15.4%
4.2%
Q3 25
15.0%
1.6%
Q2 25
22.8%
1.0%
Q1 25
23.5%
0.8%
Q4 24
18.3%
0.1%
Q3 24
23.0%
0.6%
Q2 24
18.7%
2.5%
Q1 24
15.4%
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons